Keros Therapeutics, Inc. (KROS) has seen a positive movement in its stock price following the announcement of a significant global license agreement with Takeda. On December 3, 2024, Keros disclosed that it would receive a $200 million upfront payment from Takeda, with the potential for additional milestone payments exceeding $1.1 billion. This agreement grants Takeda the exclusive rights to develop, manufacture, and commercialize elritercept, a promising treatment for anemia associated with myelodysplastic syndromes and myelofibrosis, outside of mainland China, Hong Kong, and Macau. The collaboration is expected to enhance Keros' financial position, extending its operational runway into late 2028, and further validates its leadership in the TGF-ß protein pathway.
The stock's upward movement is also supported by the recent investment by Erste Asset Management GmbH, which acquired a new stake in Keros Therapeutics valued at approximately $1.17 million. This investment reflects growing institutional interest in Keros, which has been bolstered by the company's strategic partnership with Takeda and its potential to advance innovative treatments in hematologic oncology.
Keros Therapeutics' stock is currently trading at $62.99, reflecting a 1.14% increase from its previous close of $62.28.